The Business of GLP-1 Weight-Loss Drugs: Market Growth, Side Effects, and Accessibility

The Rise of GLP-1 Drugs

• 💡 GLP-1 based drugs, known by brand names like Ozempic, Wegovy, and Zepbound, have emerged as a significant disruptor in the pharmaceutical world, particularly for weight loss.
• 📈 The global market for these drugs is projected to reach $150 billion by 2035, a substantial increase from $15 billion in sales last year.

Medical and Health Implications

• 🎯 The American College of Cardiology now recommends GLP-1s as a first-line treatment for weight management in eligible patients, highlighting obesity as a pandemic in the US.
• ⚠️ While these drugs offer a potential 'miracle' for individuals with severe obesity, 50-70% of users experience side effects such as nausea and vomiting, often leading to discontinuation.
• 🔬 Long-term studies on the efficacy and side effects specifically for weight loss are limited, though they are more established for their original indication: type 2 diabetes.

Global Market Dynamics and Accessibility

• 🌍 European countries, including France, have adopted a more cautious approach to prescribing GLP-1s, prioritizing cost control for social security systems.
• 💰 In many European nations, these drugs are not reimbursed, making them unaffordable for a significant portion of the population, with monthly costs around €300 in France.
• 🇺🇸 In the US, the high cost (up to $1,000 per month) and limited insurance coverage have led to a 'gray market' where individuals import active ingredients to create their own medications.

Future Market Expansion and Challenges

• 💊 The development of oral forms of treatment, like Eli Lilly's orforgg, aims to lower prices and increase convenience.
• 🌎 Future growth is expected to be driven by middle-income countries like Brazil, India, and China, where obesity rates are rising and affordability is a key factor.
• 🔄 As drugs approach patent expiry, the introduction of generics is anticipated to significantly lower prices, making them accessible to millions more globally.
• ⚠️ The growing gray market, despite high purity tests, is considered dangerous by drug manufacturers due to the lack of regulated production processes.